Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study

. Background.  In several statin trials, vascular event rates for treatment groups begin to separate 1 year after commencement of treatment. For atherosclerosis progression, the temporal sequence of the effect has not been defined. We used data from the Measuring Effects on intima media Thickness: a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of internal medicine 2009-06, Vol.265 (6), p.698-707
Main Authors: Bots, M. L., Palmer, M. K., Dogan, S., Plantinga, Y., Raichlen, J. S., Evans, G. W., O’Leary, D. H., Grobbee, D. E., Crouse III, J. R.
Format: Article
Language:English
Subjects:
Aged
Anticholesteremic Agents - therapeutic use
atherosclerosis
Atherosclerosis (general aspects, experimental research)
Biological and medical sciences
Blood and lymphatic vessels
Cardiology. Vascular system
Carotid Artery Diseases - diagnostic imaging
Carotid Artery Diseases - drug therapy
Cholesterol, LDL - blood
Disease Progression
Double-Blind Method
Female
Fluorobenzenes - therapeutic use
General aspects
Humans
Hypercholesterolemia - prevention & control
Male
Medical sciences
Middle Aged
prevention
Pyrimidines - therapeutic use
Rosuvastatin Calcium
statin
Sulfonamides - therapeutic use
Time Factors
Treatment Outcome
trial
Tunica Intima - diagnostic imaging
Tunica Intima - drug effects
Ultrasonography
ultrasound
vascular disease
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:. Background.  In several statin trials, vascular event rates for treatment groups begin to separate 1 year after commencement of treatment. For atherosclerosis progression, the temporal sequence of the effect has not been defined. We used data from the Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin (METEOR) trial to determine the earliest time point at which significant differences in atherosclerosis progression rates could be detected after initiation of statin therapy. Methods.  The METEOR trial was a double‐blind, randomized placebo‐controlled trial that studied the effect of LDL‐C lowering with 40 mg rosuvastatin on the rate of change of carotid intima media thickness (CIMT) measured by B‐mode ultrasound amongst 984 low risk subjects. Ultrasound assessments were made at baseline and every 6 months up to 2 years. Results.  Rosuvastatin treatment was associated with a 49% reduction in LDL‐C‐C, a 34% reduction in total cholesterol, an 8.0% increase in HDL‐C and a 16% reduction in triglycerides (all P 
ISSN:0954-6820
1365-2796
DOI:10.1111/j.1365-2796.2009.02073.x